Hormonal Contraception and the Risk of Breast Cancer in Women of Reproductive Age: A Meta-Analysis
- PMID: 38067328
- PMCID: PMC10705112
- DOI: 10.3390/cancers15235624
Hormonal Contraception and the Risk of Breast Cancer in Women of Reproductive Age: A Meta-Analysis
Abstract
This study aims to summarize evidence from observational studies about the lifetime use of HC and the risk of BC in women of reproductive age. The PubMed, Cochrane, and EMBASE databases were searched for observational studies published from 2015 to February 2022. Meta-analyses were performed using adjusted odds ratios and relative risks with a random-effects model using the I2 statistic to quantify the heterogeneity among studies. Of the 724 studies identified, 650 were screened for title/abstract selection, 60 were selected for full-text revision, and 22 were included in the meta-analysis. Of these, 19 were case-control studies and 3 were cohort studies. The results of the meta-analysis indicate a significantly higher risk of developing BC in ever users of HC (pooled OR = 1.33; 95% CI = 1.19 to 1.49). This effect is larger in the subgroups of case-control studies (pooled OR = 1.44, 95% CI = 1.21 to 1.70) and in the subgroup of studies that strictly define menopausal status (pooled OR = 1.48; 95% CI, 1.10 to 2.00). Although our meta-analysis of observational studies (cohort and case-control) suggests a significantly increased overall risk of BC in users or ever-users of modern hormonal contraceptives, the high heterogeneity among studies (>70%) related to differences in study design, measurement of variables, confounders, among other factors, as well as publication biases should be considered when interpreting our results.
Keywords: breast cancer; hormonal contraception; meta-analysis; premenopausal; risk factors.
Conflict of interest statement
The authors declare that they have no known competing financial interest or personal relationships that could appear to influence the work reported in this paper.
Figures







Similar articles
-
Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.Cochrane Database Syst Rev. 2023 May 15;5(5):CD014908. doi: 10.1002/14651858.CD014908.pub3. Cochrane Database Syst Rev. 2023. PMID: 37184292 Free PMC article. Review.
-
The relationship between central obesity and risk of breast cancer: a dose-response meta-analysis of 7,989,315 women.Front Nutr. 2023 Nov 9;10:1236393. doi: 10.3389/fnut.2023.1236393. eCollection 2023. Front Nutr. 2023. PMID: 38024370 Free PMC article.
-
Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.Hum Reprod Update. 2023 Mar 1;29(2):197-217. doi: 10.1093/humupd/dmac038. Hum Reprod Update. 2023. PMID: 36383189 Free PMC article.
-
The effect of exposure to radiofrequency fields on cancer risk in the general and working population: A systematic review of human observational studies - Part I: Most researched outcomes.Environ Int. 2024 Sep;191:108983. doi: 10.1016/j.envint.2024.108983. Epub 2024 Aug 30. Environ Int. 2024. PMID: 39241333
-
Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study.BMJ. 2018 Sep 26;362:k3609. doi: 10.1136/bmj.k3609. BMJ. 2018. PMID: 30257920 Free PMC article.
Cited by
-
Contraceptive use with breast cancer incidence in Indonesia.Breast Dis. 2024;43(1):127-134. doi: 10.3233/BD-249007. Breast Dis. 2024. PMID: 38788058 Free PMC article.
-
Personality traits of women with hereditary risk for breast/ovarian cancer versus obstetric history and cancer preventive behaviors.Sci Rep. 2025 Jan 25;15(1):3218. doi: 10.1038/s41598-025-87657-6. Sci Rep. 2025. PMID: 39863726 Free PMC article.
References
-
- Kanadys W., Barańska A., Malm M., Błaszczuk A., Polz-Dacewicz M., Janiszewska M., Jędrych M. Use of Oral Contraceptives as a Potential Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis of Case-Control Studies Up to 2010. Int. J. Environ. Res. Public Health. 2021;18:4638. doi: 10.3390/ijerph18094638. - DOI - PMC - PubMed
-
- Knutson T.P., Truong T.H., Ma S., Brady N.J., Sullivan M.E., Raj G., Schwertfeger K.L., Lange C.A. Posttranslationally Modified Progesterone Receptors Direct Ligand-Specific Expression of Breast Cancer Stem Cell-Associated Gene Programs. J. Hematol. Oncol. 2017;10:89. doi: 10.1186/s13045-017-0462-7. - DOI - PMC - PubMed
-
- Horseman N.D., Zhao W., Montecino-Rodriguez E., Tanaka M., Nakashima K., Engle S.J., Smith F., Markoff E., Dorshkind K. Defective Mammopoiesis, but Normal Hematopoiesis, in Mice with a Targeted Disruption of the Prolactin Gene. EMBO J. 1997;16:6926–6935. doi: 10.1093/emboj/16.23.6926. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources